Journal List > Korean J Gastroenterol > v.74(4) > 1135711

Park: Second Primary Cancer after Treating Gastrointestinal Cancer

Abstract

Advances in diagnosis and therapeutic technologies have brought increased life expectancy for most cancers, but paradoxically it also has increased the risk of second primary malignancies. Cancer survivors have a higher risk of developing cancer than the general population. This suggests that more studies are needed to develop screen and management programs for cancer survivors, especially patients with gastrointestinal cancers, which are the most common cancers in Korea.

Figures and Tables

Fig. 1

Five-year survival rates (%) of cancer at all sites, stomach, colon, liver, and bile duct according to the year of diagnosis from 1993 to 2016 in Korea.4

kjg-74-193-g001

Notes

Financial support None.

Conflict of interest None.

References

1. Chung JW, Chung MJ, Bang S, et al. Assessment of the risk of colorectal cancer survivors developing a second primary pancreatic cancer. Gut Liver. 2017; 11:728–732.
crossref
2. Dong C, Hemminki K. Second primary neoplasms in 633,964 cancer patients in Sweden, 1958-1996. Int J Cancer. 2001; 93:155–161.
crossref
3. Tabuchi T, Ito Y, Ioka A, Miyashiro I, Tsukuma H. Incidence of metachronous second primary cancers in Osaka, Japan: update of analyses using population-based cancer registry data. Cancer Sci. 2012; 103:1111–1120.
crossref
4. Jung KW, Won YJ, Kong HJ, Lee ES. Cancer Statistics in Korea: incidence, mortality, survival, and prevalence in 2016. Cancer Res Treat. 2019; 51:417–430.
crossref
5. Shin DW, Cho B, Kim SY, Jung JH, Park JH. Management of cancer survivors in clinical and public health perspectives: current status and future challenges in Korea. J Korean Med Sci. 2013; 28:651–657.
crossref
6. Curtis RE, Freedman DM, Ron E. New malignancies among cancer survivors: SEER cancer registries, 1973–2000. Bethesda (MD): National Cancer Institute;2006.
7. Dong C, Hemminki K. Second primary neoplasms among 53 159 haematolymphoproliferative malignancy patients in Sweden, 1958–1996: a search for common mechanisms. Br J Cancer. 2001; 85:997–1005.
crossref
8. Morais S, Antunes L, Bento MJ, Lunet N. Risk of second primary cancers among patients with a first primary gastric cancer: a population-based study in North Portugal. Cancer Epidemiol. 2017; 50(Pt A):85–91.
crossref
9. Guan X, Jin Y, Chen Y, et al. The incidence characteristics of second primary malignancy after diagnosis of primary colon and rectal cancer: a population based study. PLoS One. 2015; 10:e0143067.
crossref
10. Nielsen SF, Nordestgaard BG, Bojesen SE. Associations between first and second primary cancers: a population-based study. CMAJ. 2012; 184:E57–E69.
crossref
11. Jo JH, Cho IR, Jung JH, et al. Clinical characteristics of second primary pancreatic cancer. PLoS One. 2017; 12:e0179784.
crossref
12. Lee JE, Shin DW, Lee H, et al. One-year experience managing a cancer survivorship clinic using a shared-care model for gastric cancer survivors in Korea. J Korean Med Sci. 2016; 31:859–865.
crossref
13. Jung HY. Current status of endoscopic resection of early gastric cancer in Korea. Korean J Gastroenterol. 2017; 70:121–127.
crossref
14. Shah BK, Khanal A, Hewett Y. Second primary malignancies in adults with gastric cancer - a US population-based study. Front Oncol. 2016; 6:82.
crossref
15. Chen SC, Liu CJ, Hu YW, et al. Second primary malignancy risk among patients with gastric cancer: a nationwide population-based study in Taiwan. Gastric Cancer. 2016; 19:490–497.
crossref
16. Kim C, Chon H, Kang B, et al. Prediction of metachronous multiple primary cancers following the curative resection of gastric cancer. BMC Cancer. 2013; 13:394.
crossref
17. Kim JW, Jang JY, Chang YW, Kim YH. Clinical features of second primary cancers arising in early gastric cancer patients after endoscopic resection. World J Gastroenterol. 2015; 21:8358–8365.
crossref
18. Kim JY, Jang WY, Heo MH, et al. Metachronous double primary cancer after diagnosis of gastric cancer. Cancer Res Treat. 2012; 44:173–178.
crossref
19. Phipps AI, Chan AT, Ogino S. Anatomic subsite of primary colorectal cancer and subsequent risk and distribution of second cancers. Cancer. 2013; 119:3140–3147.
crossref
20. Lee YT, Liu CJ, Hu YW, et al. Incidence of second primary malignancies following colorectal cancer: a distinct pattern of occurrence between colon and rectal cancers and association of co-morbidity with second primary malignancies in a population-based cohort of 98,876 patients in Taiwan. Medicine (Baltimore). 2015; 94:e1079.
21. Dasgupta P, Youlden DR, Baade PD. Multiple primary cancers among colorectal cancer survivors in Queensland, Australia, 1996-2007. Cancer Causes Control. 2012; 23:1387–1398.
crossref
22. Yun HR, Yi LJ, Cho YK, et al. Double primary malignancy in colorectal cancer patients--MSI is the useful marker for predicting double primary tumors. Int J Colorectal Dis. 2009; 24:369–375.
crossref
23. Wu WC, Chen YT, Hwang CY, et al. Second primary cancers in patients with hepatocellular carcinoma: a nationwide cohort study in Taiwan. Liver Int. 2013; 33:616–623.
crossref
24. Zhuang L, Yan X, Meng Z. Second primary malignancy in patients with cholangiocarcinoma: a population-based study. Cancer Manag Res. 2019; 11:1969–1983.
25. Shin DW, Baik YJ, Kim YW, et al. Knowledge, attitudes, and practice on second primary cancer screening among cancer survivors: a qualitative study. Patient Educ Couns. 2011; 85:74–78.
crossref
26. Shin DW, Cho J, Yang HK, et al. Oncologists' experience with patients with second primary cancer and the attitudes toward second primary cancer screening: a nationwide survey. Cancer Res Treat. 2015; 47:600–606.
crossref
TOOLS
ORCID iDs

Jeong Youp Park
https://orcid.org/0000-0003-0110-8606

Similar articles